336 related articles for article (PubMed ID: 18165419)
1. ACOG Practice Bulletin No. 89. Elective and risk-reducing salpingo-oophorectomy.
ACOG
Obstet Gynecol; 2008 Jan; 111(1):231-41. PubMed ID: 18165419
[No Abstract] [Full Text] [Related]
2. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
[TBL] [Abstract][Full Text] [Related]
3. Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.
Kenkhuis MJ; de Bock GH; Elferink PO; Arts HJ; Oosterwijk JC; Jansen L; Mourits MJ
Maturitas; 2010 Jul; 66(3):310-4. PubMed ID: 20409655
[TBL] [Abstract][Full Text] [Related]
4. Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy.
Powell CB
Gynecol Oncol; 2006 Jan; 100(1):1-2. PubMed ID: 16368438
[No Abstract] [Full Text] [Related]
5. Prophylactic oophorectomy in women at increased cancer risk.
Domchek SM; Rebbeck TR
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848
[TBL] [Abstract][Full Text] [Related]
6. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.
Biglia N; Mariani L; Ponzone R; Sismondi P
Maturitas; 2008 Jun; 60(2):71-7. PubMed ID: 18472232
[No Abstract] [Full Text] [Related]
7. Risk-reducing salpingo-oophorectomy for BRCA mutation carriers.
Haldar K; Crawford R
Maturitas; 2010 Nov; 67(3):290. PubMed ID: 20869823
[No Abstract] [Full Text] [Related]
8. Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy.
Gynecol Oncol; 2005 Aug; 98(2):179-81. PubMed ID: 15979696
[No Abstract] [Full Text] [Related]
9. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
Mahajan NN
Cancer; 2007 Dec; 110(12):2819; author reply 2819-20. PubMed ID: 17969078
[No Abstract] [Full Text] [Related]
10. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers.
Carcangiu ML; Radice P; Manoukian S; Spatti G; Gobbo M; Pensotti V; Crucianelli R; Pasini B
Int J Gynecol Pathol; 2004 Jan; 23(1):35-40. PubMed ID: 14668548
[TBL] [Abstract][Full Text] [Related]
11. Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers.
Chapman JS; Powell CB; McLennan J; Crawford B; Mak J; Stewart N; Chen LM
Gynecol Oncol; 2011 Aug; 122(2):339-43. PubMed ID: 21531449
[TBL] [Abstract][Full Text] [Related]
12. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
13. Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers.
Madalinska JB; van Beurden M; Bleiker EM; Valdimarsdottir HB; Lubsen-Brandsma L; Massuger LF; Mourits MJ; Gaarenstroom KN; van Dorst EB; van der Putten H; Boonstra H; Aaronson NK
J Clin Oncol; 2007 Jan; 25(3):301-7. PubMed ID: 17235045
[TBL] [Abstract][Full Text] [Related]
14. CA125 screening after risk-reducing salpingo-oophorectomy: are the titers too high, or is it all just too much?
Bradford LS; Schorge JO
Menopause; 2011 Feb; 18(2):123-4. PubMed ID: 21191312
[No Abstract] [Full Text] [Related]
15. Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense?
Olivier RI; Lubsen-Brandsma LA; van Boven H; van Beurden M
Gynecol Oncol; 2005 Feb; 96(2):439-43. PubMed ID: 15661233
[TBL] [Abstract][Full Text] [Related]
16. Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube?
Cass I; Walts A; Karlan BY
Gynecol Oncol; 2010 Apr; 117(1):27-31. PubMed ID: 20110118
[TBL] [Abstract][Full Text] [Related]
17. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy.
Dowdy SC; Stefanek M; Hartmann LC
Am J Obstet Gynecol; 2004 Oct; 191(4):1113-23. PubMed ID: 15507929
[TBL] [Abstract][Full Text] [Related]
18. Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development.
Leblanc E; Narducci F; Farre I; Peyrat JP; Taieb S; Adenis C; Vennin P
Gynecol Oncol; 2011 Jun; 121(3):472-6. PubMed ID: 21411127
[TBL] [Abstract][Full Text] [Related]
19. Oophorectomy in carriers of BRCA mutations.
Whitfield GA
N Engl J Med; 2002 Sep; 347(13):1037-40; author reply 1037-40. PubMed ID: 12353513
[No Abstract] [Full Text] [Related]
20. Cancer antigen 125 level after a bilateral salpingo-oophorectomy: what is the contribution of the ovary to the cancer antigen 125 level?
van Altena AM; Holtsema H; Hendriks JC; Massuger LF; de Hullu JA
Menopause; 2011 Feb; 18(2):133-7. PubMed ID: 20861755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
